Inclusion Criteria:

• Are ≥ 18 years at the Screening Visit.
• Have met clinical diagnostic criteria for typical CIDP, or one of the following CIDP variants: multifocal CIDP, focal CIDP, or motor CIDP in accordance with the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on the Diagnosis and Treatment of CIDP. Clinical criteria for typical CIDP and variants are as follows (either criteria must be met):
• Typical CIDP: All the following:
  • Progressive or relapsing, symmetric, proximal, and distal muscle weakness of upper and lower limbs, and sensory involvement of at least two limbs (at any point in the disease course);
  • Developing over at least 8 weeks;
  • Absent or reduced tendon reflexes in all limbs.
• CIDP variants: One of the following, but otherwise as in typical CIDP (tendon reflexes may be normal in unaffected limbs):
  • Multifocal CIDP: documented sensory loss and muscle weakness in a multifocal pattern, usually asymmetric, upper limb predominant;
  • Focal CIDP: sensory loss and muscle weakness in only one limb;
  • Motor CIDP: motor symptoms and signs without sensory involvement.
• Have electrodiagnostic test results supporting the diagnosis of CIDP in accordance with the EAN/PNS Guideline on the Diagnosis and Treatment of CIDP (either criteria must be met):
  • Motor nerve conduction criteria strongly supportive of demyelination.
  • Motor nerve conduction criteria weakly supportive of demyelination and 2 or more of the following additional diagnostic criteria:
    • Objective improvement to an empiric trial of therapy with immunoglobulin treatment, plasma exchange (PLEX) or corticosteroids.
• Diagnostic imaging by ultrasound or magnetic resonance imaging (MRI) supporting the diagnosis of CIDP by demonstrating nerve enlargement.
• Cerebrospinal fluid (CSF) demonstrating albuminocytologic dissociation (i.e., elevated CSF protein level [defined as > 70 milligrams per deciliter {mg/dL} or more than 10 mg/dL greater than years of age for those aged 60 years and over] with normal CSF white blood cell [WBC] level).
• Nerve biopsy demonstrating features supporting the diagnosis of CIDP such as edema, demyelination, and/or onion bulb formation.
• Additional inclusion criteria are defined in the protocol.

Exclusion Criteria:

• Have presence of immunoglobulin M (IgM) paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies.
• Have Distal CIDP, Sensory CIDP or are suspected of having a diagnosis of auto-immune nodopathy in accordance with the EAN/PNS Guideline on the Diagnosis and Treatment of CIDP.
• Have polyneuropathy of causes other than CIDP including but not limited to:
  • Multifocal motor neuropathy;
  • Hereditary demyelinating neuropathy;
  • Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes (i.e., POEMS);
  • Lumbosacral radiculoplexus neuropathy;
  • Systemic illnesses including vitamin deficiency syndromes and paraneoplastic neuropathies;
  • Drug- or toxin-induced.
• Have diabetes mellitus (DM) and meets any of the following criteria:
  • Diagnosis of DM pre-dates the diagnosis of CIDP;
  • Has ever required daily insulin therapy;
  • Duration of DM is 5 years or greater;
  • Has evidence of microvascular complications of DM including retinopathy or nephropathy.
• Have a history of myelopathy or evidence of central demyelination.
• Are receiving chronic oral corticosteroids monotherapy at a dose > 40 mg/day or < 20 mg/day prednisolone/prednisone or its equivalent at the Screening Visit.
• Are receiving chronic oral corticosteroid at a dose > 10 mg/day prednisone or equivalent in combination with immunoglobulin therapy or PLEX at the Screening Visit.
• Additional exclusion criteria are defined in the protocol.

Eligibility last updated 6/2/23. Questions regarding updates should be directed to the study team contact.